Brief: Innate Pharma Advances Lacutamad Clinical Development Program

Innate Pharma SA

09/02/2021 06:11

Feb 9 (Reuters) - Innate Pharma SA  IPH.PA :
    * REG-INNATE PHARMA ADVANCES LACUTAMAB CLINICAL DEVELOPMENT
PROGRAM
    * TELLOMAK TRIAL PROGRESSES AS COHORT 2 OF
KIR3DL2-EXPRESSING
MYCOSIS FUNGOIDES PATIENTS ADVANCES TO STAGE 2 EARLIER THAN
ANTICIPATED
    * RECRUITMENT IS ONGOING IN COHORT 3, EVALUATING LACUTAMAB
AS A
MONOTHERAPY IN KIR3DL2 NON-EXPRESSING MF PATIENTS
    * COMPANY PLANS TO PRESENT PRELIMINARY DATA AT A SCIENTIFIC
MEETING IN 2021

Source text for Eikon:  ID:nGNX9cZdQZ 
Further company coverage:  IPH.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00 ;))